sacituzumab govitecan (ASCENT) (mOS=∼11.8 month

Quote:

---

sacituzumab govitecan (ASCENT) (mOS=∼11.8 months, 1 year ∼25%, 2 years 20%).

Pooled analysis of the 3 studies showed from time of leronlimab treatment; mOS 6.8 months (95% CI: 4.4-17.7), survival at 1 yr. 41.3% (95% CI 22.7-59., 2 yr. 24.8% (95% CI:8.0-41.5), and 3 yr. 19.8% (95% CI: 3.8-35.8%). 4 patients who are currently alive without evidence of disease after 42, 48, 49, and 52, months, each had 4 prior lines of systemic therapy and were treated with leronlimab either in combination or subsequently, with checkpoint inhibitors: pembrolizumab (N=1) or atezolizumab (N=3) and chemotherapy (N=4).

---

I was hoping we'd get an update on the mOS in the 525mg/700mg group. A 65% increase in survival at one year and a 24% at two years over Trodelvy is amazing even if you don't take into account sub-optimal dosing, an often later stage patient population and brain and bone metastasis being excluded from the Trodelvy trial.